Prestige Consumer Healthcare Inc. (NYSE:PBH) SVP Mary Beth Fritz Sells 9,885 Shares of Stock

Prestige Consumer Healthcare Inc. (NYSE:PBH) SVP Mary Beth Fritz sold 9,885 shares of the firm’s stock in a transaction that occurred on Tuesday, November 12th. The stock was sold at an average price of $81.97, for a total value of $810,273.45. Following the transaction, the senior vice president now owns 18,835 shares of the company’s stock, valued at $1,543,904.95. This trade represents a 34.42 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Prestige Consumer Healthcare Stock Performance

NYSE PBH traded down $0.68 during trading hours on Friday, reaching $82.11. 16,810 shares of the company were exchanged, compared to its average volume of 249,609. Prestige Consumer Healthcare Inc. has a 1 year low of $56.61 and a 1 year high of $83.83. The business’s 50 day simple moving average is $72.98 and its 200-day simple moving average is $70.09. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The stock has a market capitalization of $4.06 billion, a P/E ratio of 20.15, a P/E/G ratio of 2.32 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 7th. The company reported $1.09 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business had revenue of $283.79 million during the quarter, compared to the consensus estimate of $282.09 million. During the same quarter last year, the company posted $1.07 earnings per share. The firm’s quarterly revenue was down .9% compared to the same quarter last year. On average, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.45 earnings per share for the current year.

Institutional Trading of Prestige Consumer Healthcare

A number of large investors have recently added to or reduced their stakes in PBH. Ariel Investments LLC boosted its position in Prestige Consumer Healthcare by 10.7% during the second quarter. Ariel Investments LLC now owns 2,835,203 shares of the company’s stock worth $195,204,000 after purchasing an additional 274,212 shares during the period. Victory Capital Management Inc. boosted its position in shares of Prestige Consumer Healthcare by 9.0% in the second quarter. Victory Capital Management Inc. now owns 2,074,460 shares of the company’s stock valued at $142,827,000 after acquiring an additional 171,357 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Prestige Consumer Healthcare by 19.3% in the third quarter. Allspring Global Investments Holdings LLC now owns 1,575,170 shares of the company’s stock valued at $113,570,000 after acquiring an additional 255,045 shares during the period. Congress Asset Management Co. boosted its position in shares of Prestige Consumer Healthcare by 7.8% in the third quarter. Congress Asset Management Co. now owns 865,123 shares of the company’s stock valued at $62,375,000 after acquiring an additional 62,411 shares during the period. Finally, Boston Trust Walden Corp bought a new position in shares of Prestige Consumer Healthcare in the third quarter valued at approximately $41,785,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on PBH. DA Davidson reaffirmed a “buy” rating and issued a $95.00 price target on shares of Prestige Consumer Healthcare in a research note on Monday. Jefferies Financial Group reissued a “hold” rating and issued a $76.00 target price (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $94.20.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.